Zanthoxylum zanthoxyloides

Zanthoxylum zanthoxyloides contains cytotoxic alkaloids (collinin, fagaronine, acetoxyschinifolin), antioxidant flavonoids (neohesperidin, hesperidin, quercetin), and terpenoids (squalene, limonene) that collectively exert antimicrobial, hepatoprotective, and antiproliferative effects through free-radical scavenging and mitotic arrest. In preclinical models, a flavonoid-enriched shoot extract demonstrated an LC50 of 85.52 μg/mL in brine shrimp cytotoxicity assays, and an alkaloidal fraction achieved IC50 values of 4.62–22.1 μM against cancer cell lines including PC-3 prostate cells, while animal doses of 50–200 mg/kg significantly improved CCl4-induced liver injury markers (p<0.05).

Origin & History

Zanthoxylum zanthoxyloides is a deciduous shrub or small tree native to sub-Saharan Africa, distributed across the Sahel and savanna zones from Senegal and Gambia eastward through Nigeria, Niger, and into East Africa. It thrives in dry woodland, scrubland, and laterite soils at low to mid elevations, often found in association with other Sahelian flora. The plant belongs to the Rutaceae (citrus) family and has been harvested primarily from wild populations, with roots, bark, leaves, and fruits all used in traditional medicine systems including Hausa, Yoruba, and other West African ethnomedicinal traditions.

Historical & Cultural Context

Zanthoxylum zanthoxyloides, known regionally as 'African prickly ash' or 'Senegal prickly ash,' holds a prominent position in West African traditional medicine, most notably within the Hausa medicinal system of northern Nigeria and Niger, where root bark is habitually chewed to relieve toothache, treat oral infections, and manage febrile illnesses including malaria. The species is also employed by Yoruba, Mandinka, and Wolof healers across the Sahel belt, with applications spanning treatment of sexually transmitted infections, sickle cell anemia crisis management, rheumatic pain, and as a general tonic—uses documented in ethnobotanical surveys conducted from the 1970s onward. Traditional preparation most commonly involves direct chewing of fresh root bark, decoction of root and stem bark in water for oral or topical use, or leaf infusions administered as antipyretics; the pungent taste attributed to alkaloids and terpenoids is itself considered therapeutically significant in local healing epistemology. The plant's role as a chewing stick places it alongside other Zanthoxylum species used globally for oral hygiene, reflecting convergent ethnobotanical knowledge across Africa and Asia within the Rutaceae family.

Health Benefits

- **Antioxidant Activity**: Flavonoid-rich shoot extracts scavenge DPPH, nitric oxide, and hydrogen peroxide radicals at levels statistically superior to crude ethanolic extracts (p<0.05), attributable to neohesperidin, hesperidin, quercetin, and norchelerythrine in root bark, though activity remains below that of ascorbic acid at equivalent concentrations.
- **Hepatoprotective Effects**: In a CCl4-induced hepatocellular carcinoma-like rat model (n=49), ethanolic extracts at 50–200 mg/kg orally over 12 weeks significantly reduced serum gamma-glutamyl transferase (GGT), improved liver histology, and normalized liver-to-body weight ratios (p<0.05), suggesting protection against oxidative liver damage.
- **Anticancer Potential**: Isolated alkaloids collinin (IC50 4.62–6.26 μM), 8-methoxyanisocoumarin H (IC50 5.02–33.5 μM), and acetoxyschinifolin (IC50 5.12–35.11 μM) demonstrate dose-dependent cytotoxicity against multiple cancer cell lines in vitro, with fagaronine also documented as an antiproliferative agent in the ethnopharmacological literature.
- **Antimicrobial Activity**: Methanolic and ethanolic extracts from various plant parts show concentration-dependent inhibition of bacterial and fungal growth, with minimum inhibitory concentrations determined by log-response curves; this activity partially rationalizes the traditional use of chewed root bark as a dental analgesic and antimicrobial dentifrice in Hausa communities.
- **Antimalarial Properties**: Consistent with its documented Hausa ethnomedicinal use against malaria, phytoconstituents including alkaloids and flavonoids of the Zanthoxylum genus are associated with antiprotozoal mechanisms, though species-specific in vivo antimalarial efficacy data for Z. zanthoxyloides require further characterization in controlled studies.
- **Anti-inflammatory Potential**: Quercetin, hesperetin, and hyperoside identified across roots, stems, and fruits are established inhibitors of pro-inflammatory cyclooxygenase and lipoxygenase pathways at the compound class level, providing a phytochemical rationale for the plant's traditional use in pain and fever management, including toothache relief.
- **Antiproliferative / Antimitotic Activity**: Root bark and shoot extracts arrest cell division in the Allium cepa (onion root) mitotic index assay, a validated phytogenotoxicity screen, indicating interference with spindle fiber assembly or cell cycle checkpoint regulation relevant to both anticancer and antiparasitic applications.

How It Works

The antioxidant effects of Z. zanthoxyloides are primarily mediated by phenolic flavonoids—neohesperidin, hesperidin, quercetin, norchelerythrine, eriocitrin, hyperoside, and hesperetin—which donate hydrogen atoms to neutralize DPPH, superoxide, nitric oxide, and hydrogen peroxide radicals through their catechol and resorcinol ring structures, thereby reducing oxidative stress-driven cellular damage. Cytotoxic alkaloids including collinin, fagaronine, and acetoxyschinifolin are thought to intercalate into DNA or inhibit topoisomerase activity (consistent with the benzo[c]phenanthridine and furoquinoline alkaloid classes to which they belong), triggering apoptotic cascades in rapidly dividing cells at sub-micromolar to low-micromolar concentrations. The hepatoprotective mechanism appears to involve suppression of lipid peroxidation and reduction of CCl4-activated CYP2E1-generated trichloromethyl radical damage, with concurrent improvement in hepatocyte membrane integrity as reflected by normalized serum GGT levels. Antimitotic activity in the Allium cepa model suggests interference with tubulin polymerization or spindle checkpoint proteins, though precise molecular gene targets and receptor-level interactions have not yet been characterized for this species.

Scientific Research

The entirety of the published evidence base for Z. zanthoxyloides consists of in vitro cell-line studies, ex vivo bioassays (brine shrimp nauplii lethality, Allium cepa mitotic index), and one in vivo rat hepatotoxicity model (n=49; 7 rats per group); no human clinical trials, randomized controlled trials, or systematic reviews have been conducted or registered as of the available literature. The rat hepatoprotection study employed oral doses of 50–200 mg/kg of ethanolic extract over 12 weeks and reported statistically significant improvements in GGT, liver histology, and organ-weight ratios (p<0.05), representing the strongest in vivo efficacy signal but with severe limitations in translational validity due to small group sizes and a single animal model. Cytotoxicity data for isolated alkaloids (collinin IC50 4.62–6.26 μM; acetoxyschinifolin IC50 5.12–35.11 μM against cancer cell lines) are derived from standard in vitro assays and provide proof-of-concept but cannot predict therapeutic windows, pharmacokinetics, or clinical outcomes in humans. Phytochemical characterization studies using GC-MS and HPLC (identifying squalene, vitamin E, neohesperidin, hesperidin, quercetin, and multiple alkaloids) are methodologically credible but do not quantify absolute concentrations in mg/g across tissues, limiting dose-response extrapolation; the overall evidence level is preclinical and exploratory.

Clinical Summary

No clinical trials in human subjects have been conducted on Zanthoxylum zanthoxyloides for any indication, including its primary traditional uses of toothache relief and malaria treatment in Hausa medicine. The most advanced in vivo evidence comes from a single CCl4-hepatotoxicity rat model study demonstrating hepatoprotective effects at 50–200 mg/kg with statistically significant improvements in liver biomarkers (p<0.05), though the small group sizes (n=7/group) substantially limit confidence in these findings. In vitro cytotoxicity and antioxidant assays provide pharmacologically plausible mechanisms but do not constitute clinical evidence of efficacy or safety in humans, and no standardized human dose, bioavailability estimate, or therapeutic index has been established. Confidence in any clinical application of Z. zanthoxyloides extracts must be considered very low; the compound profile warrants further preclinical dose-escalation, ADMET profiling, and ultimately controlled human studies before any therapeutic claims can be substantiated.

Nutritional Profile

Zanthoxylum zanthoxyloides is not consumed as a food and has no conventional macronutrient or micronutrient profile; its phytochemical composition is its primary nutritional-pharmacological relevance. GC-MS analysis of shoot extracts identifies alpha-tocopherol (vitamin E) and squalene as lipid-soluble constituents, alongside monoterpenes 3-carene and limonene. Flavonoid constituents quantified by HPLC across plant parts include neohesperidin and hesperidin (highest in roots and trunk barks), quercetin (higher in roots and trunks than fruits), eriocitrin (fruits), hyperoside, and hesperetin (roots, stems, fruits); absolute mg/g concentrations have not been reported in available literature. Alkaloid constituents include collinin, fagaronine, atanine, norchelerythrine, 8-methoxyanisocoumarin H, and acetoxyschinifolin. Additional phytochemicals detected in crude extracts include saponins, tannins, glycosides, steroids, and carbohydrates. Bioavailability data for any constituent from this specific plant are absent; however, flavonoids from the hesperidin and quercetin classes are generally subject to intestinal glucosidase-dependent deglycosylation prior to absorption, with oral bioavailability typically in the range of 15–50% based on analogue studies.

Preparation & Dosage

- **Traditional Chewing Stick (Root Bark)**: Fresh or dried root bark segments are chewed directly as a dental analgesic and antiseptic dentifrice; no standardized length or dose established, used ad hoc in West African traditional practice.
- **Crude Ethanolic Shoot Extract (Research Use)**: Prepared by Soxhlet extraction or maceration with 70–96% ethanol; used in preclinical studies at concentrations yielding LC50 99.58 μg/mL in brine shrimp assay; no human dose established.
- **Flavonoid-Enriched Extract (Research Use)**: Prepared by liquid-liquid partitioning of crude ethanolic extract; demonstrates superior antioxidant and cytotoxic activity (LC50 85.52 μg/mL) compared to crude extract; no commercial standardization or human dose available.
- **Alkaloidal Leaf Extract (Research Use)**: Isolated via Soxhlet extraction followed by acid-base liquid-liquid partitioning; administered orally to rats at 50–200 mg/kg for hepatoprotection studies; human equivalent dose not calculated or validated.
- **Methanolic Extracts (Fruits, Leaves, Stems, Barks, Roots)**: Used in phytochemical and antimicrobial characterization studies; no human supplemental form or standardized commercial preparation exists.
- **Essential Oil (Leaves)**: Obtained by hydrodistillation; contains 3-carene and limonene; studied for aromatic and potential antimicrobial properties only; no dosage established.
- **Note**: No recommended daily intake, standardization percentage, or approved supplemental form exists for human consumption; all dosage references are experimental preclinical values only.

Synergy & Pairings

Within West African polyherbal formulations, Z. zanthoxyloides root bark is often co-administered with Moringa oleifera or Azadirachta indica (neem) for synergistic antimicrobial and antipyretic effects, with the alkaloid fraction of Z. zanthoxyloides potentially enhancing cellular permeability to companion phytochemicals, though mechanistic synergy studies are absent. The quercetin and hesperidin content of Z. zanthoxyloides theoretically synergizes with vitamin C (ascorbic acid) through flavonoid-ascorbate redox cycling, regenerating oxidized ascorbyl radicals and amplifying net antioxidant capacity—a mechanism well-characterized for quercetin-vitamin C pairings in other botanical systems. Pairing with piperine-containing spices such as Piper guineense (African black pepper), used in the same traditional pharmacopoeia, may improve alkaloid bioavailability by inhibiting intestinal P-glycoprotein and CYP3A4-mediated first-pass metabolism, though this specific combination has not been studied for Z. zanthoxyloides.

Safety & Interactions

No formal human safety studies, toxicological dose-escalation trials, or adverse event reports have been published for Zanthoxylum zanthoxyloides preparations; the available animal data (50–200 mg/kg orally over 12 weeks in rats) showed no overt hepato- or nephrotoxicity, and liver and kidney biomarkers were improved versus the CCl4 control group, but these findings cannot be directly extrapolated to establish a human safe dose. The cytotoxic alkaloids present (collinin, fagaronine, acetoxyschinifolin) with IC50 values in the low micromolar range against cancer cell lines indicate a meaningful antiproliferative potential that raises concern for genotoxicity or teratogenicity at high doses; the Allium cepa mitotic arrest data further underscore this risk, and use during pregnancy or lactation cannot be considered safe given the absence of reproductive toxicity data. Drug interaction data are entirely absent; however, by analogy with related Zanthoxylum species and the alkaloid/flavonoid content, potential interactions with cytochrome P450 enzymes (particularly CYP3A4 and CYP1A2), anticoagulants, and antimalarial drugs are pharmacologically plausible and warrant caution. No maximum safe human dose, tolerable upper intake level, or contraindication list has been formally established; use should be approached with significant caution outside traditional contexts, and individuals with liver disease, blood-clotting disorders, or those taking prescription medications should consult a qualified healthcare provider before use.